AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27128606
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (SD) of GSK2018682 up to 24 mg
Trial: 27128606
Drug: Repeat dose
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat dose (RD) of GSK2018682 up to 6 mg/day for 28 days
Trial: 27128606
Drug: GSK2018682 RD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GSK2018682 RD of 6 mg
Trial: 17823517
Drug: Pimecrolimus 1%
RxNorm normalized name: PIMECROLIMUS 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 1% cream applied twice daily for 7 days
Trial: 17823517
Drug: Placebo applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo applied twice daily for 7 days
Trial: 1534729
Drug: Lactase treatment
RxNorm normalized name: Lactase
DrugBank: Tilactase (DB13761)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactase treatment (9900 FCC units, 3 chewable tablets)
Trial: 1534729
Drug: Lactase treatment
RxNorm normalized name: Lactase
DrugBank: Tilactase (DB13761)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactase treatment
Trial: 30077803
Drug: Dialectical Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavior Therapy (DBT) skills group
Trial: 24812071
Drug: Integrated intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated intervention including monthly breastfeeding learning sessions, weekly text and voice messages, and participant-generated songs and dramas.
Trial: 22250885
Drug: Self‐administered computer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐administered computer therapy targeting whole word production with error reduction strategies
Trial: 19281013
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (acupuncture, obturation, needle-knife)
Trial: 17229323
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g alcohol (one drink)
Trial: 17229323
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g alcohol (two drinks)
Trial: 16333887
Drug: Injection sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection sclerotherapy with adjuvant propranolol (40 mg tds)
Trial: 16333887
Drug: Injection sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection sclerotherapy only
Trial: 16333887
Drug: Injection sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection sclerotherapy with adjuvant propranolol
Trial: 12223437
Drug: High-fiber group
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber group (13.5 g/day)
Trial: 12223437
Drug: Low-fiber group
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fiber group (2.0 g/day)
Trial: 12223437
Drug: Supplemental fiber
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental fiber intake greater than 11.0 g/day
Trial: 12223437
Drug: Total fiber
RxNorm normalized name: Konsyl CARE TOTAL FIBER Psyllium Fiber 6g Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total fiber intake greater than 30.3 g/day
Trial: 9653495
Drug: FU-Plus-LV (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FU-Plus-LV (400 mg/m2/day FU + 20 mg/m2/day LV for 5 days)
Trial: 9653495
Drug: FU Alone
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FU Alone (400 mg/m2/day FU)
Trial: 7858400
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion rate < 6.0 mg.kg‐1.h‐1
Trial: 7858400
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion rate > 6.0 mg.kg‐1.h‐1
Trial: 31977699
Drug: Microneedling therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedling therapy
Trial: 31033013
Drug: Melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (5 mg) in dim light (10 lux)
Trial: 31033013
Drug: Melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (5 mg) in bright light (2000 lux)
Trial: 12583942
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg salmeterol twice daily (n=372)
Trial: 12583942
Drug: 500 microg
RxNorm normalized name: Etizolam 500 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 microg fluticasone twice daily (n=374)
Trial: 12583942
Drug: 50 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microg salmeterol and 500 microg fluticasone twice daily (n=358)
Trial: 1783346
Drug: Gelofalk (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelofalk (a combination of smectite, aluminium hydroxide, and magnesium hydroxide)
Trial: 1783346
Drug: Aluminium hydroxide
RxNorm normalized name: Aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminium hydroxide antacid (control)
Trial: 7211892
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of medroxyprogesterone (MPG) daily for approximately one month
Trial: 26905220
Drug: Routine heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine heart failure treatment (Control)
Trial: 26905220
Drug: Responders to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responders to BNP-guided therapy
Trial: 26905220
Drug: Non-responders to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-responders to BNP-guided therapy
Trial: 25213052
Drug: Lansoprazole treatment
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole treatment
Trial: 19618317
Drug: Atorvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin treatment for 8 weeks
Trial: 17243866
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3) (10 microg or 400 IU) plus calcium (1000 mg/day)
Trial: 15331942
Drug: Citrate plus
RxNorm normalized name: Walgreens Calcium Citrate Plus D3 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate plus low-dose heparin
Trial: 11978136
Drug: Systemic corticosteroids
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic corticosteroids (100 to 200 mg/day in the initial phase)
Trial: 11978136
Drug: Cyclosporine (mainly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (mainly as maintenance treatment)
Trial: 11978136
Drug: Combinations of
RxNorm normalized name: Combinations of vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combinations of corticosteroids with cytotoxic drugs (azathioprine, cyclophosphamide, chlorambucil)
Trial: 11978136
Drug: Corticosteroids with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids with sulfa drugs (dapsone, clofazimine, minocycline, thalidomide)
Trial: 11978136
Drug: Local application
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local application of granulocyte-macrophage colony-stimulating factor, intravenous immunoglobulins, plasmapheresis
Trial: 11978136
Drug: Topical therapy
RxNorm normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical therapy with modern wound dressings
Trial: 11978136
Drug: Systemic antibacterial
RxNorm normalized name: Trimethoprim and derivatives, systemic antibacterials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic antibacterial therapy
Trial: 31832638
Drug: Cotrimoxazole treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole treatment (CTX-T)
Trial: 31832638
Drug: No cotrimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cotrimoxazole treatment (CTX-N)
Trial: 19535429
Drug: Conjugated linoleic
RxNorm normalized name: CONJUGATED LINOLEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated linoleic acid (CLA) (8 g oil/d)
Trial: 19535429
Drug: Safflower oil
RxNorm normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower oil (SAF) (8 g oil/d)
Trial: 11449087
Drug: Estrogen group
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen group (21 tablets with 20 microg of ethinyl‐estradiol and 150 mg of desogestrel for 21 days, followed by 2 placebo tablets and 5 ethinyl‐estradiol tablets of 10 microg each)
Trial: 11449087
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (21 tablets with 20 microg of ethinyl‐estradiol and 150 mg of desogestrel for 21 days, followed by 7 placebo tablets)
Trial: 7839843
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no metallic implant)
Trial: 2835245
Drug: Intravenous L-648,051
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-648,051 (35, 52.5, and 70 mg/5 min infusion)
Trial: 2835245
Drug: Aerosolized L-648,051
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized L-648,051 (0.1 to 1.6 mg)
Trial: 31511279
Drug: Oligosaccharide-sialic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligosaccharide-sialic acid (OS) preparation
Trial: 27687823
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy group (EG) - home‐based progressive strength and aerobic training program for 12 months
Trial: 27687823
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care group (UCG) - received only oral and written instructions of exercises
Trial: 27687823
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy group (EG)
Trial: 19165529
Drug: MPH ER
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MPH ER (10 mg/day to 60 mg/day)
Trial: 9229881
Drug: Indomethacin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 0.1 mg/kg bolus followed by continuous infusion 0.1 mg/kg/h
Trial: 9229881
Drug: Indomethacin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 0.2 mg/kg bolus followed by continuous infusion 0.2 mg/kg/h
Trial: 9229881
Drug: Indomethacin 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 0.3 mg/kg bolus followed by continuous infusion 0.3 mg/kg/h
Trial: 8387576
Drug: Standard-dose cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose cisplatin (SDCP) 50 mg/m2 days 1 and 8 on a 28-day cycle for eight cycles
Trial: 8387576
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin (HDCP) 100 mg/m2 days 1 and 8 for four cycles
Trial: 8387576
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin plus mitomycin (HDCP-M) 8 mg/m2 day 1
Trial: 2893636
Drug: Ketanserin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (mean daily dose 77 mg)
Trial: 2893636
Drug: Nifedipine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (mean daily dose 62 mg)
Trial: 28568974
Drug: 1600 mg
RxNorm normalized name: glycerin 1600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 mg mesalazine tablets (3.2 g oral mesalazine, administered as two 1600 mg tablets once daily)
Trial: 28568974
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg mesalazine tablets (4 tablets twice daily)
Trial: 7241435
Drug: 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg terbutaline sulphate inhaled at 25 1/min
Trial: 7241435
Drug: 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg terbutaline sulphate inhaled at 80 1/min
Trial: 7241435
Drug: 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg terbutaline sulphate inhaled at 25 1/min with 20% vital capacity
Trial: 7241435
Drug: 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg terbutaline sulphate inhaled at 25 1/min with 50% vital capacity
Trial: 7241435
Drug: 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg terbutaline sulphate inhaled at 25 1/min with 80% vital capacity
Trial: 7241435
Drug: 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg terbutaline sulphate inhaled at 80 1/min with 20% vital capacity
Trial: 7241435
Drug: 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg terbutaline sulphate inhaled at 80 1/min with 50% vital capacity
Trial: 7241435
Drug: 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg terbutaline sulphate inhaled at 80 1/min with 80% vital capacity
Trial: 31678536
Drug: Double-targeted DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-targeted DNA vaccine of Vibrio mimicus
Trial: 26306418
Drug: Behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural therapy intervention provided by trained pharmacists (stimulus control and sleep restriction) over three pharmacy visits (baseline, 1 and 3 months follow-up)
Trial: 19833998
Drug: Abstinence-contingent housing,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abstinence-contingent housing, vocational training, work, plus cognitive behavioral day treatment
Trial: 19833998
Drug: Consecutive weeks
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consecutive weeks of abstinence during treatment
Trial: 15658951
Drug: BIBN4096BS 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBN4096BS 2.5 mg
Trial: 15658951
Drug: BIBN4096BS 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBN4096BS 10 mg
Trial: 15658951
Drug: BIBN4096BS (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBN4096BS (2.5 mg and 10 mg)
Trial: 2181623
Drug: Chewable antacid
RxNorm normalized name: CALCIUM CARBONATE 500 mg ORAL TABLET, CHEWABLE [CALCIUM CARBONATE CHEWABLE ANTACID]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewable antacid tablet (30 mmol) four times daily
Trial: 7418711
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of hydrochlorothiazide daily
Trial: 7418711
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg of reserpine daily
Trial: 31812464
Drug: IVACFLU-A/H5N1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVACFLU-A/H5N1 vaccine (15 mcg)
Trial: 30455160
Drug: Daily lottery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily lottery incentives tied to achievement of weight loss goals
Trial: 30455160
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of incentives and environmental strategies
Trial: 24506910
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vitamin D supplementation (2000 IU/day)
Trial: 24506910
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose vitamin D supplementation (400 IU/day)
Trial: 22306855
Drug: HPV4 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV4 vaccine (standard schedule: 0, 2, 6 months)
Trial: 22306855
Drug: HPV4 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV4 vaccine (modified schedule: 0, 3, 6 months)
Trial: 29156321
Drug: Clear aligners
RxNorm normalized name: Caladryl Clear
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clear aligners treatment after 6 months
Trial: 27619782
Drug: Mirabegron add-on
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron add-on treatment with tamsulosin
Trial: 24428704
Drug: DS‐ALL treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS‐ALL treatment
Trial: 24428704
Drug: Non-DS ALL
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-DS ALL treatment
Trial: 22414766
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg BI 207127 TID
Trial: 22414766
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg BI 207127 TID
Trial: 22414766
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg BI 207127 TID
Trial: 18837602
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with brief alcohol intervention (ST-BI)
Trial: 11045266
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplementation (ferrous sulfate 325 mg, 195 mg elemental iron, three times daily for 4 months)
Trial: 11045266
Drug: Intravenous total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous total dose iron (ITDI) (1 g iron dextran mixed in 1/2 normal saline, single infusion over 4 hours for 4 months)
Trial: 9299215
Drug: Acetazolamide 250
RxNorm normalized name: acetazolamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250 mg tablets
Trial: 8420437
Drug: UK-74,505 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK-74,505 (100 mg)
Trial: 27821598
Drug: HOME BP
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HOME BP online digital intervention with self-monitoring, lifestyle advice and antihypertensive drug titration
Trial: 22070357
Drug: Propranolol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (up to 240 mg/day for 19 days)
Trial: 19587388
Drug: CP‐690,550 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP‐690,550 5 mg twice daily
Trial: 19587388
Drug: CP‐690,550 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP‐690,550 15 mg twice daily
Trial: 19587388
Drug: CP‐690,550 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP‐690,550 30 mg twice daily
Trial: 10347337
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 to 10 mg once a day)
Trial: 10347337
Drug: Nitrendipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (5 to 10 mg once a day)
Trial: 8942585
Drug: Large-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Large-dose aprotinin (ALD)
Trial: 8942585
Drug: Small-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Small-dose aprotinin (ASD)
Trial: 6189039
Drug: Chemotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy treatment based on two cytostatic drug combinations (cyclophosphamide, adriamycin, vincristine, methotrexate, bleomycin, 5‐fluorouracil, procarbazine)
Trial: 29930812
Drug: GSK2838232 (5-250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2838232 (5-250 mg single doses, 20-200 mg repeat doses)
Trial: 29930812
Drug: GSK2838232 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2838232 with RTV (up to 200 mg once or twice daily)
Trial: 29930812
Drug: GSK2838232 (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2838232 (50-100 mg without RTV, 50-250 mg with RTV)
Trial: 29930812
Drug: Micronized formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized formulation of GSK2838232
Trial: 24703208
Drug: Uric acid
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uric acid 1000 mg
Trial: 19208703
Drug: Topical alkane
RxNorm normalized name: C12-19 alkane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical alkane vapocoolant spray (n=103)
Trial: 19208703
Drug: Water spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water spray (control, n=98)
Trial: 17324401
Drug: Capsule Endoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule Endoscopy (CE) followed by Push Enteroscopy (PE) if necessary
Trial: 11680669
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rizatriptan (oral dose)
Trial: 2666705
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with cardiac glycosides and vasodilators (2% nitroglycerin ointment, nitrosorbide or molsidomin)
Trial: 31916662
Drug: Mid-treatment QIDS-4
RxNorm normalized name: Acne Treatment 4 % - 5 % Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-treatment QIDS-4
Trial: 28057872
Drug: Etelcalcetide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etelcalcetide (5 mg initially, adjusted to 2.5-15 mg over 12 weeks)